Clinical trial
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive…
NCT01892345 · Alexion Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT01892345 |
|---|---|
| Title | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder |
| Intervention type | Drug |
| Interventions | Eculizumab, Placebo |
| Enrollment | 143 |
| Start date | Apr 11, 2014 |
| Primary completion | Jul 17, 2018 |
| Completion | Jul 17, 2018 |
| First posted | Jul 4, 2013 |
| Last update posted | Jun 26, 2019 |
| Countries | Argentina, Australia, Croatia, Czechia, Denmark, Germany, Hong Kong, Italy, Japan, Malaysia, Russia, South Korea and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: